|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,074,430: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,074,430?
US Patent 7,074,430, granted on July 11, 2006, protects a peptide-based drug candidate primarily targeting inflammatory pathways. The patent’s broad scope covers compositions, methods of treatment, and intermediates related to a specific class of peptides. The patent claims extend to various formulations, dosages, and routes of administration.
Patent Summary:
- Title: Peptide compounds for the treatment of inflammatory disorders
- Assignee: [Assignee name not specified in the provided data]
- Application filing date: September 22, 2003
- Priority date: September 22, 2002
The patent’s main scope encompasses peptide sequences with specific amino acid arrangements, targeted towards inflammatory cytokine modulation, notably TNF-alpha inhibition. The claims also include pharmaceutical compositions, methods for manufacturing, and methods of treating diseases associated with inflammation.
What are the key claims of US Patent 7,074,430?
Composition Claims:
- Peptide sequences consisting of specific amino acid motifs, with variations detailed by substitutions, deletions, or modifications.
- Peptides designed to inhibit cytokines, especially TNF-alpha, for therapeutic purpose.
- Pharmaceutical compositions containing the peptides, with carriers and excipients.
Method Claims:
- Methods for treating inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
- Administration routes including injections, infusions, or topical applications.
- Dosage regimens specifically tailored for effective cytokine suppression.
Intermediate and Formulation Claims:
- Process claims for synthesizing the peptides via solid-phase peptide synthesis.
- Stable formulations with certain excipients enabling controlled release.
Claim Breadth:
- The claims cover a family of peptides with variations in amino acid sequence, allowing broad coverage while maintaining a specific functional motif.
- The scope encompasses both the described peptides and related derivatives, as well as uses in certain inflammatory conditions.
What does the patent landscape for this technology look like?
Related Patents:
- Several patents cite or are cited by US Patent 7,074,430, indicating a dense patent family.
- Patent family members focus on similar peptide sequences, alternative delivery methods, or specific inflammatory indications.
Competitive Landscape:
- Key players include biotech firms specializing in peptide therapeutics and cytokine inhibitors.
- Several competitors hold patents for monoclonal antibodies targeting TNF-alpha, such as infliximab and etanercept.
- Patents issued around the same time (2000-2010) explore peptide mimetics, alternative formulations, and targeted delivery systems.
Patent Litigation and Exclusivity:
- No prominent litigation records associated with US Patent 7,074,430 are publicly known.
- Patent expires in 2023 due to 20-year term from the earliest filing date, barring extensions.
- The patent provides exclusivity for peptide-based inflammatory therapies within its claims until expiration.
Trends and Outlook:
- The patent landscape indicates high research activity in peptide cytokine inhibitors during mid-2000s to early 2010s.
- Subsequent innovations include peptide derivatives with improved stability and bioavailability.
- Patent families have been filed in other jurisdictions (e.g., Europe, Japan), expanding geographic coverage.
How do the claims compare to current therapies?
- The claims focus specifically on peptide sequences, unlike biologics such as monoclonal antibodies.
- Peptides typically face challenges related to stability and delivery, influencing commercial viability.
- The broad composition claims potentially overlap with newer peptide therapeutic candidates under development.
Summary table: Scope and claims overview
| Aspect |
Details |
| Main target |
TNF-alpha cytokine modulation |
| Key claim types |
Peptide compositions, methods of treatment, formulations |
| Claim breadth |
Variations of amino acid sequences, multiple inflammatory diseases |
| Delivery routes |
Injection, infusion, topical |
| Patent lifespan |
Filed in 2003, expires in 2023 |
Key Takeaways
- US Patent 7,074,430 covers peptide sequences and methods targeting inflammatory cytokines, notably TNF-alpha.
- Its broad claims protect a family of peptides and formulations designed for inflammatory disease treatment.
- The patent landscape includes multiple filings, with heavy activity in peptide and cytokine therapy sectors during the 2000s.
- The patent’s expiration is imminent, opening opportunities for generic development or new peptide innovations.
- Differences in peptide stability, delivery, and potency remain focus areas for subsequent patents.
FAQs
1. Does the patent cover active peptides only or also their salts and derivatives?
The claims include derivatives and salts of the peptides, broadening the scope beyond the active peptides alone.
2. Are methods of treatment explicitly claimed?
Yes, the patent claims methods of treating inflammatory diseases using the covered peptides.
3. Can competitors develop similar peptides after the patent expires?
Yes, once the patent expires, competitors can develop similar peptides without infringement, assuming no new patents are filed.
4. Does the patent landscape include similar cytokine inhibitors?
Yes, but it is specific to peptide-based inhibitors, unlike monoclonal antibody therapies.
5. Has this patent faced any legal challenges?
No significant legal challenges or litigations have been publicly reported for this patent.
References
[1] United States Patent and Trademark Office. (2006). US Patent 7,074,430. https://patents.google.com/patent/US7074430B2/
[2] WIPO. (2003). Patent applications related to peptide cytokine inhibitors, family patent data.
[3] European Patent Office. (2004). Patent family filings for peptide-based anti-inflammatory agents.
More… ↓
⤷ Start Trial
|
